These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 2050518)

  • 1. Claudication: an unusual side effect of DHE administration.
    Schulman EA; Rosenberg SB
    Headache; 1991 Apr; 31(4):237-9. PubMed ID: 2050518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ergotamine tartrate and dihydroergotamine mesylate: safety profiles.
    Lipton RB
    Headache; 1997; 37 Suppl 1():S33-41. PubMed ID: 9009472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Migraine: dihydroergotamine nasal spray--an alternative].
    Beubler E
    Wien Med Wochenschr; 1995; 145(14):326-31. PubMed ID: 7483646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine.
    Silberstein S
    Expert Opin Pharmacother; 2012 Sep; 13(13):1961-8. PubMed ID: 22860628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [A case of hyposphygmia caused by ergotamine in migraine].
    Pulici S; Roncoroni G
    Minerva Med; 1975 Feb; 66(13):612-6. PubMed ID: 1113911
    [No Abstract]   [Full Text] [Related]  

  • 6. Ergot pharmacology and alternative delivery systems for ergotamine derivatives.
    Goldstein J
    Neurology; 1992 Mar; 42(3 Suppl 2):45-6. PubMed ID: 1557192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Double-blind, multicenter trial to compare the efficacy of intramuscular dihydroergotamine plus hydroxyzine versus intramuscular meperidine plus hydroxyzine for the emergency department treatment of acute migraine headache.
    Carleton SC; Shesser RF; Pietrzak MP; Chudnofsky CR; Starkman S; Morris DL; Johnson G; Rhee KJ; Barton CW; Chelly JE; Rosenberg J; Van Valen MK
    Ann Emerg Med; 1998 Aug; 32(2):129-38. PubMed ID: 9701293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine.
    Saper JR; Silberstein S
    Headache; 2006 Nov; 46 Suppl 4():S171-81. PubMed ID: 17078849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydroergotamine nasal spray for the acute treatment of migraine.
    Ziegler D; Ford R; Kriegler J; Gallagher RM; Peroutka S; Hammerstad J; Saper J; Hoffert M; Vogel B; Holtz N
    Neurology; 1994 Mar; 44(3 Pt 1):447-53. PubMed ID: 8145914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine: current perspectives.
    Young WB
    Headache; 1997; 37 Suppl 1():S42-5. PubMed ID: 9009473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is orally inhaled dihydroergotamine (DHE) equivalent in efficacy in migraine to intravenous DHE?
    Tfelt-Hansen P
    Headache; 2014 Feb; 54(2):383. PubMed ID: 24512579
    [No Abstract]   [Full Text] [Related]  

  • 12. Orally inhaled dihydroergotamine: a review.
    Tepper SJ
    Headache; 2013 Sep; 53 Suppl 2():43-53. PubMed ID: 24024602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Working Panel of the Headache and Facial Pain Section of the American Academy of Neurology.
    Silberstein SD; Young WB
    Neurology; 1995 Mar; 45(3 Pt 1):577-84. PubMed ID: 7898722
    [No Abstract]   [Full Text] [Related]  

  • 14. Dihydroergotamine (DHE) - Then and Now: A Narrative Review.
    Silberstein SD; Shrewsbury SB; Hoekman J
    Headache; 2020 Jan; 60(1):40-57. PubMed ID: 31737909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Where is dihydroergotamine mesylate in the changing landscape of migraine therapy?
    Morren JA; Galvez-Jimenez N
    Expert Opin Pharmacother; 2010 Dec; 11(18):3085-93. PubMed ID: 21080856
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repetitive intravenous DHE in the treatment of refractory headache.
    Silberstein SD; Schulman EA; Hopkins MM
    Headache; 1990 May; 30(6):334-9. PubMed ID: 2370132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy.
    Tas C; Joyce JC; Nguyen HX; Eangoor P; Knaack JS; Banga AK; Prausnitz MR
    J Control Release; 2017 Dec; 268():159-165. PubMed ID: 29051065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with patient administered subcutaneous dihydroergotamine mesylate in refractory headaches.
    Klapper JA; Stanton J
    Headache; 1992 Jan; 32(1):21-3. PubMed ID: 1372884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome.
    Eller M; Gelfand AA; Riggins NY; Shiboski S; Schankin C; Goadsby PJ
    Neurology; 2016 Mar; 86(9):856-9. PubMed ID: 26843569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine.
    Touchon J; Bertin L; Pilgrim AJ; Ashford E; Bès A
    Neurology; 1996 Aug; 47(2):361-5. PubMed ID: 8757005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.